TROG Cancer Research
Members Login   CQMS Login

Head & Neck trials now recruiting

 

TROG 12.01 (HPV) - this study aims to compare radiotherapy combined with either cetuximab or cisplatin in patients with locoregionally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC) (located at the base of tongue or tonsil).

Primary sponsor: TROG

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.